Cargando…

SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Detalles Bibliográficos
Autores principales:	Nuijten, M, Mickisch, G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813753/ https://www.ncbi.nlm.nih.gov/pubmed/20051962 http://dx.doi.org/10.1038/sj.bjc.6605446

Ejemplares similares

Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Nuijten, M, et al.
Publicado: (2010)

Reply: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Thompson Coon, J S, et al.
Publicado: (2010)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
por: Shah, Amishi Y., et al.
Publicado: (2015)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
por: Wang, Y, et al.
Publicado: (2014)

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
por: Izzedine, Hassane, et al.
Publicado: (2011)

Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group
por: Grünwald, V., et al.
Publicado: (2022)

28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
por: Magdy, A., et al.
Publicado: (2015)

DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
por: Peters, Inga, et al.
Publicado: (2014)

Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib
por: Ferrer, Florent, et al.
Publicado: (2021)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
por: Peng, Bo, et al.
Publicado: (2017)

Long-term survival in unfavourable-risk mRCC patients after intratumoral administration of a cell-based allogeneic vaccine
por: Karlsson-Parra, Alex, et al.
Publicado: (2015)

Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
por: Boegemann, Martin, et al.
Publicado: (2021)

AB116. Clinical efficacy and safety of molecular targeted drugs as first-line treatment for mRCC: a systematic review and network meta-analysis
por: Mo, Chengqiang, et al.
Publicado: (2014)

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
por: Grünwald, Viktor, et al.
Publicado: (2012)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)
por: Saad, Eddy, et al.
Publicado: (2023)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
por: Barata, Pedro, et al.
Publicado: (2020)

Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?
por: Eggers, Hendrik, et al.
Publicado: (2022)

Regulatory T-Cells and Associated Pathways in Metastatic Renal Cell Carcinoma (mRCC) Patients Undergoing DC-Vaccination and Cytokine-Therapy
por: Schwarzer, Adrian, et al.
Publicado: (2012)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022)

Interferon (IFNγ) induces cell cycle arrest in RCC cell lines
por: Tate, David J, et al.
Publicado: (2013)

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
por: Seidel, C, et al.
Publicado: (2013)

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough
por: Mollica, Veronica, et al.
Publicado: (2021)

The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape
por: Doehn, Christian, et al.
Publicado: (2022)

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
por: Ornstein, Moshe C., et al.
Publicado: (2019)

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G, et al.
Publicado: (2010)

Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
por: Liguori, Luigi, et al.
Publicado: (2023)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications
por: Hahn, Andrew W., et al.
Publicado: (2017)

SUN-479 Metastatic Renal Cell Carcinoma (RCC) to the Thyroid: Case Report and Clinical Lesson
por: Reddy, Sreedevi Singidi, et al.
Publicado: (2020)

Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated (18)F–Fluorodeoxyglucose ((18)F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study
por: Kelly-Morland, Christian, et al.
Publicado: (2017)

Data supporting the roles of BAP1, STING, and IFN-β in ISGF3 activation in ccRCC
por: Langbein, Lauren E., et al.
Publicado: (2022)

Verifying the accuracy of statistical significance testing in Campbell Collaboration systematic reviews through the use of the R package statcheck
por: Polanin, Joshua R., et al.
Publicado: (2018)

Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)
por: Erbe, Amy K, et al.
Publicado: (2015)

Coronavirus survival on beach sand: Sun vs COVID-19
por: Efstratiou, Maria Adamantia, et al.
Publicado: (2021)

A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC
por: Piao, Xuan-Mei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g3pcpfu24vv7em302p0tqja5cn